Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Once Daily Empagliflozin 25 mg for the Treatment of Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass
Antonio Ferreira(University of Bern), Lia Bally(Diabetes Australia), Joanna Gawinecka(University Hospital of Zurich), Marc Y. Donath(University of Basel), Christos T. Nakas(University of Bern), Andreas Melmer(University of Bern), David Herzig(University of Bern), Matthias Hepprich(University Hospital of Basel), Daniel Giachino(Lindenhofspital), Natascha Potoczna(Hirslanden Klinik St. Anna), Andreas Vogt(University of Bern), Daniel G. Fuster(University of Bern), Philipp C. Nett(University of Bern), Chiara Dalla Man(University of Padua), Andrea Facchinetti(University of Padua), Luca Cossu(University of Padua), Katja A. Schönenberger(University of Bern), Jörg Zehetner(Hirslanden Klinik Beau-Site), Philipp A. Gerber(University of Zurich)
Cited by 13
Related Papers
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
|New England Journal of Medicine|2021|509
Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice
|Endocrine Reviews|2022|398
IL-1 family nomenclature
|Nature Immunology|2010|341
Fully Integrated Artificial Pancreas in Type 1 Diabetes
|Diabetes|2012|310